Fortune, April 7, 2021. There’s a big problem with clinical trials: a lack of diversity. This problem led researchers to believe that Black women did not develop breast cancer as frequently as white women and created a gap in understanding how different treatments work. How can companies like Genentech start increasing diversity in clinical trials?
Read More »Tag: clinical trials
Congressman calls for FDA to continue vaccine trials
ABC, December 29, 2020. Rep. Llyod Doggett of Texas wrote to the FDA urging COVID-19 clinical trials to continue until they have more data.
Read More »How the Coronavirus Pandemic May Affect Cancer Clinical Trials
Cancer Therapy Advisor, August 18, 2020. The dangers of Covid-19, especially to cancer patients, are upending access to clinical trials for cancer treatments.
Read More »National Center for Health Research’s Public Comments on FDA’s Proposed Inclusion of Older Adults in Cancer Clinical Trials Guidance for Industry
May 4, 2020: We strongly support FDA’s efforts to improve the diversity of clinical trials and analyses of demographic subgroups, but have been disappointed that these efforts have not been enforced in a meaningful way.
Read More »NCHR Comments on FDA’s OMHHE Strategic Priorities
February 28, 2020. Efforts to improve inclusion of racial and ethnic minority populations in clinical trials need to include incentives that are more effective than merely asking companies to do so. Greater diversity would, in turn, improve the generalizability of clinical trial results and provide patients and health care professionals with the information necessary to make an informed decision about which products to use for which patients.
Read More »